Increasing Investments in Pharmaceutical Industry to Accelerate Growth of Global Acute Coronary Syndrome Drugs Market

Published Date : Nov 28, 2016

ALBANY, NY, Nov 28, 2016: The 416-page research study, titled “PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis To 2025,” provides a thorough assessment of the market. The study is expected to help readers and market players identify emerging players with a strong product portfolio and design effective counter-strategies in order to gain a competitive edge. An insightful review of the key drivers, barriers, and challenges has been provided in the scope of the research study.

Acute coronary syndrome is considered to be a serious medical condition, which is characterized by reduced and impulsive flow of blood to the heart. Key symptoms of acute coronary syndrome are somewhat similar to those of a heart attack, such as pressure in the chest. With technological advancements in the healthcare sector, several drugs and therapeutics are available for patients with acute coronary syndrome. The rising emphasis of key players on the expansion of product portfolio and the introduction of effective drugs and therapeutics is estimated to encourage the growth of the global acute coronary syndrome drugs market.

The growing geriatric population and the rising prevalence of acute coronary syndrome are the key factors augmenting the global market. In addition, the rising investments in pharmaceutical research and development activities and the emergence of innovative and effective drugs are expected to accelerate the growth of the global acute coronary syndrome drugs market throughout the forecast period. The increasing number of obese people worldwide and the rising prevalence of diabetes are expected to hold mammoth opportunities for the growth of the global market for acute coronary syndrome drugs.

For Sample Copy, click here:

On the flip side, stringent regulations concerning drug approvals are expected to restrict the growth of the overall market in the coming years. In addition, the less number of approved drugs for treating patients with acute coronary syndrome is projected to hamper the market’s growth. Nonetheless, the rising number of mergers and acquisitions and strategic collaborations between drug manufacturing companies and the increasing number of product launches are expected to accelerate the growth of the acute coronary syndrome drugs market in the forecast period. Moreover, a large pipeline of drugs with properties including improved safety and high patient compliance is encouraging the growth of the global market.

The research study offers a detailed competitive reports of the global acute coronary syndrome drug market. The company overview, financial status, recent developments, business strategies, and SWOT reports of the leading players have been discussed in the study. Some of the key players operating in the global market are Cerenis Therapeutics, Amgen, Eli Lilly, Esperion Therapeutics, Daiichi Sankyo, Sanofi, GlaxoSmithKline, Pfizer, Merck & Co., Janssen, AstraZeneca, CSL Limited, Bristol-Myers Squibb, and The Medicines Company.

To order report Call Toll Free: 866-997-4948 or send an email on